X. Wang et al. / Tetrahedron Letters 45 (2004) 8355–8358
8357
O
O
OTf
n-Bu
n-Bu
NaBH4/MeOH
3N HCl
O
Pd(OAc)2/dppp
79%
O
15
O
OH
14
4
O
O
OH
N3
Tf2O/CH2Cl2
TEA
(PhO)2PON3
88%
BH3-THF
(R)-CBS
40%, 3 steps
18
17
OH
16
8a
92%, 91.5%ee
NH2
F3C
CHO
Ph3P/THF-H2O
92%, 92% ee
20
1
NaBH(OAc)3/HOAc
90%
19
Scheme 5.
7. The two isomers were separated by preparative HPLC.
Column = X-terra C-18 RP, 10l; column size =
5cm · 30cm; particle size = 10l; wavelength = 220nm;
cycle time/per cycle = 20min; total separation time for
each injection = 80min; sample loading/per injection:
0.55g; mobile phase = 45/55/MeCN/H2O; tempera-
ture = 25ꢁC; sample concentration = 22mg/mL; injection
volume = 25mL; flow rate = 120mL/min. Compound 9a:
1H NMR (300MHz, CDCl3): 2.25 (2H, dt), 2.57 (3H, s),
3.01 (2H, t), 6.05 (1H, dt), 6.45 (1H, d), 7.12 (1H, d), 7.19
(1H, dd), 7.45 (1H, d). 13C NMR (75MHz, CDCl3): 23.2,
24.6, 30.4, 125.6, 127.1, 127.3, 127.9, 129.5, 135.3, 135.7,
138.2, 202.8. Compound 9b: 1H NMR (300MHz, CDCl3):
2.21 (2H, m), 2.59 (3H, s), 2.79 (1H, t), 6.15 (1H, dt), 7.02
(1H, d), 7.12 (1H, d), 7.19 (1H, dd), 7.45 (1H, d). 13C
NMR (75MHz, CDCl3): 22.3, 28.1, 29.9, 125.6, 127.1,
127.3, 127.9, 129.5, 135.3, 135.7, 138.2, 202.1.
In summary, we discovered a novel palladium catalyzed
double bond migration to afford a mixture of dihydro-
naphthalene isomers that was conducted in tandem with
the key Heck coupling reaction in a single operation.
Subsequent reductive amination was developed to afford
the target isomers. In parallel, we established an asym-
metric synthesis of the desired (R)-isomer, to unambigu-
ously correlate the stereochemical assignment.
Acknowledgements
We thank Dr. Paul J. Reider for his useful discussion
and consistent encouragement. We sincerely thank Dr.
Mike Martinelli for extensive proofreading and useful
suggestions. We are also grateful to Bo Shen, Mike
Ronk and Duncan Smith for technical assistance with
HPLC, MS and NMR.
8. Chiral HPLC separation was achieved: Chirobiotic
V column 150 · 4.6mm; wavelength = 260nm; mobile
phase = MeOH/HOAc/TEA 1000/0.2/0.2 (v:v:v); flow
rate = 1mL/min; column temperature = ambient. Com-
1
pound 1: H NMR (400MHz, CDCl3): 7.40 (1H, s); 7.26
References and notes
(3H, m); 7.21 (2H, m); 7.0 (1H, d); 6.45 (1H, d); 6.05
(1H, q); 4.59 (1H, m); 2.95 (1H, m); 2.68 (5H, m);
2.25 (2H, m); 1.91 (1H, m); 1.52 (3H, d); 13C NMR
(100MHz, CDCl3): 140.9, 134.8, 133.1, 132.9, 131.7,
130.7, 129.0, 128.8, 127.9, 127.0, 125.1, 125.0, 124.0,
123.2, 53.7, 45.2, 32.6, 27.2, 23.1, 22.9, 20.6. Compound 2:
1H NMR (400MHz, CDCl3): 7.44 (1H, d); 7.43 (1H, s);
7.38 (1H, t); 7.34 (1H, d); 7.32 (1H, d); 7.15 (1H, t); 7.02
(1H, d); 6.84 (1, d); 6.14 (1H, m); 4.16 (1H, q); 2.81 (2H, t);
2.71 (2H, m); 2.55 (2H, m); 2.29 (2H, m); 1.83 (2H, m);
1.35 (3H, d); 13C NMR (100MHz, CDCl3): 143.5, 140.9,
140.6, 136.5, 132.2, 131.7, 129.7, 129.0, 127.3, 126.5, 124.0,
125.5, 123.9, 123.0, 53.6, 47.5, 33.8, 32.2, 28.9, 23.8, 23.0.
9. For a recent example utilizing a CBS reduction of a ketone
on a kilogram scale, see: Duquette, J.; Zhang, M.; Zhu, L.;
Reeves, R. S. Org. Process Res. Dev. 2003, 7,
285.
1. Cinacalcet HCl is an oral calcimimetic drug, first in class
agent for the treatment of hyperparathyroidism and the
preservation of bone density in patients with kidney failure
or hypercalcemia due to cancer. Cinacalcet received the
FDA approval on March 8, 2004. Franceschini, N.; Joy,
M. S.; Kshirsagar, A. Expert Opin. Invest. Drugs 2003, 12,
1413.
2. 5-Hydroxy-1-tetralone was purchased from Aldrich at 5g/
$124.40.
3. Vogl, E. M.; Buchwald, S. L. J. Org. Chem. 2002, 67,
106.
4. The crude triflate 7 is not suitable for the next step and
needs purification before use.
5. Pendrak, I.; Chambers, P. A. J. Org. Chem. 1995, 60,
3249.
10. Thompson, A. S.; Humphrey, G. R.; Demarco, A. M.;
Mathre, D. J.; Grabowski, E. J. J. J. Org. Chem. 1993, 58,
5886.
6. Cruikshank, B. I.; Davies, N. R. Aust. J. Chem. 1973, 26,
1935, Olefin isomerization can also be catalyzed by other
transition metals.